Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded by Wall Street Zen to Hold Rating

Key Points

• Artiva Biotherapeutics was upgraded by Wall Street Zen from a “sell” to a “hold” rating, while other analysts remain mixed but generally constructive, with the consensus still at “Moderate Buy.”
• The stock fell 13% as investors reacted to a $300 million stock and pre-funded warrant offering, which raises dilution concerns even though it strengthens the company’s balance sheet.
• Artiva also reported positive initial AlloNK clinical data across autoimmune diseases and said the FDA agreed to a single Phase 3 trial design in refractory rheumatoid arthritis, but its latest quarterly EPS came in slightly below expectations.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Several other analysts also recently issued reports on the company. HC Wainwright upped their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a "buy" rating in a research report on Friday. Needham & Company LLC restated a "buy" rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, May 4th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $25.33.

Artiva Biotherapeutics Stock Down 13.0%

Shares of NASDAQ:ARTV opened at $10.89 on Friday. Artiva Biotherapeutics has a 52-week low of $1.47 and a 52-week high of $14.53. The stock's fifty day simple moving average is $7.59 and its 200-day simple moving average is $5.35. The company has a market capitalization of $269.20 million, a P/E ratio of -3.18 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, sell-side analysts anticipate that Artiva Biotherapeutics will post -3.33 earnings per share for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC increased its stake in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock worth $2,291,000 after acquiring an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company's stock worth $340,000 after acquiring an additional 117,733 shares during the last quarter. Renaissance Technologies LLC increased its stake in Artiva Biotherapeutics by 46.8% during the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company's stock worth $498,000 after acquiring an additional 37,053 shares during the last quarter. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics during the fourth quarter worth about $341,000. Finally, Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics during the second quarter worth about $67,000.

Key Artiva Biotherapeutics News

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva reported positive initial data for AlloNK across multiple autoimmune diseases, including a 71% ACR50 response in refractory rheumatoid arthritis patients, and said the FDA agreed to a single Phase 3 registrational trial design for AlloNK plus rituximab in refractory RA. Article Title
• Positive Sentiment: Management highlighted that the Phase 3 trial could begin in the second half of 2026, with a meaningful market opportunity in heavily pretreated rheumatoid arthritis patients, supporting the long-term bull case. Article Title
• Neutral Sentiment: Artiva also reported first-quarter 2026 results and outlined recent business progress, reinforcing investor focus on the company’s pipeline and upcoming clinical milestones. Article Title
• Neutral Sentiment: The company’s quarterly loss was slightly worse than expected, but the earnings miss was not the main market-moving catalyst compared with the clinical updates and financing news. Article Title
• Negative Sentiment: Artiva priced a $300 million stock and pre-funded warrant offering, which likely pressured the shares because it increases dilution even as it strengthens the balance sheet. Article Title
• Negative Sentiment: Investor enthusiasm for the strong data appeared to be tempered by concern that the financing may offset some of the upside from the trial progress. Article Title

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.